Aldeyra Therapeutics (ALDX)

Aldeyra Therapeutics (ALDX) Income Statement


Aldeyra Therapeutics Income Statement

Last quarter (Q1 2023), Aldeyra Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q1, Aldeyra Therapeutics's net income was $-15.62M. See Aldeyra Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
--$ 0.00$ 0.00$ 0.00$ 0.00
Cost of Revenue
Gross Profit
Operating Expense
$ 35.61M$ 62.68M$ 56.22M$ 34.67M$ 56.51M$ 39.70M
Operating Income
$ -63.00M$ -62.68M$ -56.22M$ -34.67M$ -56.51M$ -39.70M
Net Non Operating Interest Income Expense
$ 2.15M$ 655.35K$ -1.56M$ -1.61M$ 937.50K$ 805.91K
Other Income Expense
$ -61.68K--$ -1.75M$ -6.57M-
Pretax Income
$ -60.85M$ -62.02M$ -57.78M$ -38.03M$ -62.14M$ -38.89M
Tax Provision
--$ 0.00$ -479.26K$ -1.31M$ 0.00
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
$ -60.85M$ -62.02M$ -57.78M$ -37.55M$ -60.83M$ -38.89M
Basic EPS
$ -6.68M$ -1.06$ -1.07$ -1.11$ -2.24$ -1.79
Diluted EPS
$ -0.50$ -1.06$ -1.07$ -1.11$ -2.24$ -1.79
Basic Average Shares
$ 233.96M$ 58.41M$ 54.04M$ 33.97M$ 27.11M$ 21.69M
Diluted Average Shares
$ 233.96M$ 58.41M$ 54.04M$ 33.97M$ 27.11M$ 21.69M
Dividend Per Share
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
Rent Expense Supplemental
Total Expenses
$ 35.61M$ 62.68M$ 56.22M$ 34.67M$ 56.51M$ 39.70M
Net Income From Continuing And Discontinued Operation
$ -60.85M$ -62.02M$ -57.78M$ -37.55M$ -60.83M$ -38.89M
Normalized Income
$ -32.33M-$ -57.78M$ -35.82M$ -54.40M$ -38.89M
Interest Expense
$ 827.31K-$ 1.74M$ 1.90M$ 603.85K$ 146.79K
$ -62.01M$ -62.68M$ -56.03M$ -36.13M$ -61.53M$ -38.75M
$ -48.04M$ -62.14M$ -55.77M$ -36.07M$ -61.44M$ -38.68M
Currency in USD

Aldeyra Therapeutics Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis